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Abstract: Genetically modified, conditionally-replicating Herpes Simplex Virus Type 1 (HSV-1) vectors for the 
treatment of malignant glioma have provided encouraging results in the handful of Phase I and Phase II clinical trials 
conducted to date. In recent years, a number of new strategies have been developed to improve anti-tumor activity of these 
attenuated vectors, through either introduction of foreign gene inserts to enhance tumor killing through a variety of 
mechanisms, or through combination with existing treatment regimens, including radiation and/or chemotherapeutics. 
Another promising new approach has been the engineering of novel oncolytic HSV vectors that retain wildtype 
replication, but are targeted to tumor cells through a variety of mechanisms. This review summarizes the latest advances 
in herpesvirus-mediated oncolytic therapies from both preclinical results and clinical trials with oncolytic HSV vectors in 
patients, and their implication for design of future trials. 
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INTRODUCTION 
  Primary and metastatic tumors arising in the brain remain 
a therapeutic challenge. For malignant glioma, the most 
frequently occurring primary brain tumor, novel treatment 
regimens have extended survival only by a few months. 
Nearly three decades ago, advancements in molecular 
biology, combined with research into viral-based 
experimental therapies for a number of malignancies 
including glioma, generated significant interest in the 
application of genetically engineered, conditionally-
replicating herpes simplex viruses (HSV-1) vectors for use 
as anti-tumor agents. A number of recent reviews of the 
history of oncolytic viral vectors, including those derived 
from HSV-1, and their application for therapy of CNS 
malignancies have summarized advances in oncolytic viral 
therapy over the past several years [1-3]. The emphasis of 
the current review is to provide an overview of the latest 
approaches and technologies utilizing both attenuated, 
conditionally replicating vectors, as well as HSV vectors that 
replicate with wildtype efficiency but in a tumor-specific 
fashion. These include: 
i)  Introduction of foreign gene inserts that enhance 
vector-mediated oncolysis through a variety of 
mechanisms; 
ii)  Use of chimeric HSV/human cytomegalovirus 
(HCMV) vectors in which introduction of the HCMV 
IRS1 or TRS1 genes into HSV backbone restores the 
wildtype protein synthesis phenotype without 
concomitant restoration of neurovirulence; 
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iii)  Combining oncolytic HSV therapy with standard of 
care therapies, including radiation and 
chemotherapeutics; 
iv)  Development of wildtype, nonattenuated HSV vectors 
that are retargeted to tumor-specific receptors; 
v)  Development of attenuated HSV vectors in which the 
HSV-1 neurovirulence gene, gamma-1 34.5 (134.5), 
discussed in more detail below, is expressed from a 
tumor-specific promoter (nestin 1); and 
vi)  Improved methods for delivery of oncolytic viral 
vectors, including convection-enhanced delivery. 
  Each of these therapies is discussed in more detail in 
subsequent subsections, and summarized schematically in 
Fig. (1). Finally, an update of latest clinical trial results, both 
recently completed and pending, is provided at the end, and 
summarized in Table 1. 
ATTENUATING MUTATIONS OF ONCOLYTIC 
HERPES SIMPLEXVIRUS VECTORS 
  dlsptk mutants In the mid to late 1970s, an HSV-1 
mutants that lacked a functional thymidine kinase gene were 
shown to be incapable of virus replication in both 
nondividing cells and in the mammalian nervous system [4]; 
subsequently, a tk deletion virus, named dlsptk, was shown 
to be capable of establishing, but not reactivating from, 
latency [5]. This HSV mutant was shown in 1991 by 
Martuza and colleagues to effectively kill glioma cell lines in 
vitro and in subcutaneous tumors, and prolonged survival of 
mice bearing intracranial tumors established from the same 
glioma cell line [6]. The tk gene deletion rendering this 
mutant resistant to antiviral agents that target the viral 
thymidine kinase prevented advancement of this virus to 
clinical trials in patients. Nonetheless, these pioneering 
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attenuating mutations could be used for specific treatment of 
rapidly growing tumors in the brain. 
  Ribonucleotide reductase mutants. The “proof of 
concept” studies from the dlsptk  mutants emphasized the 
need to develop viral vectors avirulent in normal brain but 
capable of replication in actively dividing tumor populations. 
The HSV-1 mutant hrR3 was constructed in which the 
bacterial lacZ gene was introduced within the UL39 gene 
encoding the viral ribonucleotide reductase (infected cell 
protein 6, or ICP6) [7]. The native thymidine kinase was 
retained in this construct; as such this mutant retained 
sensitivity to ganciclovir. Lack of a functional ICP6 protein 
prevented the virus from replicating in nondividing cells. 
However, in actively dividing cells, the virus was still able to 
replicate, though progeny virus recovery was reduced as 
compared to wildtype HSV. Additionally, anti-tumor activity 
of rat brain tumors following treatment with hrR3 is 
potentiated by ganciclovir treatment [8]. The HSV-1 vector 
G207 used in three Phase I clinical trials in the United States 
also contains a lacZ insertion in the UL39 gene similar to 
hrR3, in addition to deletions of both copies of the 134.5 
gene, described in the next section. 
  -1 34.5 deleted HSV mutants. In 1990, Chou and 
Roizman demonstrated that the neurovirulence function of 
HSV-1 mapped to the diploid gene 134.5, located in the 
inverted repeat sequences flanking the Unique Long (UL) 
segment of the viral genome [9]. In later studies, the normal 
function of ICP34.5, the protein product encoded by the 
134.5 gene, was shown to preclude the shutoff of host 
protein synthesis by recruitment of the host protein 
phosphatase-1a, and subsequent dephosphorylation of the 
eukaryotic translation initiation factor alpha (eIF-2) [10]. 
Normally, following infection with wild type HSV-1, 
production of double stranded RNA triggers an intracellular 
stress response that causes the protein kinase R (PKR) to 
phosphorylate eIF-2, which mediates protein synthesis 
shutoff. In normal non-mitotic cells, deletion or disruption of 
both copies of the 134.5 gene severely limit virus replication 
due to the host PKR-mediated shutoff of host protein 
synthesis. However replication of 134.5-deleted HSV can 
occur in tumor cells that possess complementing mutations. 
Examples include ras overexpression [11], and alterations in 
PKR and other cell signaling pathways [12]. Of note, 
deletion of the 134.5 gene also impacts synthesis of the 
latency-activated transcripts (LATs), encoded on 
complementary antisense DNA strands. To date, both 
oncolytic HSV vectors tested in patient clinical trials are 
based on the 134.5-deletion platform (for recent reviews, 
see [1, 2]). 
oHSV VECTORS FOR DELIVERY OF FOREIGN 
GENE-MEDIATED THERAPIES 
  Oncolytic virus therapy using HSV-1 vectors have a 
number of advantages, one being its capability for 
introduction of large transgenes for combining oHSV 
 
Fig. (1). Strategies to improve oHSV therapy of malignant glioma. Each of the different strategies discussed in detail in the text are shown 
schematically. IRS= C134 chimeric HSV expressing IRS gene from HCMV; WT= retargeted viruses that have wildtype ICP34.5 but can 
only infect cells with upregulated tumor-specific receptors; *134.5= ICP34.5 expressed from tumor-specific promoters; = 134.5 deleted 
viruses. HSV Vectors for Brain Tumor Therapy  The Open Virology Journal, 2010, Volume 4    105 
therapy with expression of foreign genes that complement 
the anti-tumor activity of the vector. There are currently a 
number of different classes of transgenes being introduced 
into oHSV vectors that are being evaluated as novel 
therapies for glioma gene therapy. These include the 
introduction of genes encoding pro-drug activating enzymes, 
tumor suppressor genes, immune modulating genes, and 
genes encoding proteins that inhibit tumor angiogenesis [13, 
14] and references therein. A number of studies by our group 
have demonstrated the antitumor efficacy of an IL-12 
expressing oHSV, M002, in both syngeneic murine brain 
tumor models and human glioma xenograft tumor models 
[15]. M002, like G207, is derived from the HSV-1 (F) strain 
with deletions in both 134.5 genes. The other notable 
difference between M002 and G207 is that in M002, the 
UL39 gene remains intact. A bicistronic expression cassette 
encoding interleukin-12 p40 and p35 subunits from either 
murine (M002) or human (M032) origin, and separated by an 
internal ribosome entry sequence (IRES), were introduced 
into both 134.5 deleted sites. Production of a cGMP lot of 
M032 for Phase I clinical trials through the NCI 
Biopharmaceutical Development Program (BDP) has 
recently been completed, and submission of an IND 
application for approval by the United States Food and Drug 
Administration (FDA) is planned for summer 2010. 
CHIMERIC HSV/HCMV 
  Preclinical and clinical evidence indicates that tumor cells 
can escape 134.5 first generation oncolytic HSV treatment 
[16, 17]. One hypothesis is that these mutants are unable to 
maintain prolonged replication in the tumor, and therefore their 
ability to spread throughout the tumor mass is compromised by 
the innate antiviral host responses. To counteract these 
responses impeding 134.5 HSV replication in infected tumor 
cells, the IRS1 gene from a distantly related herpesvirus, Human 
Cytomegalovirus (HCMV), was introduced into a 134.5 HSV 
background. IRS-1 has been previously demonstrated to 
selectively restore late viral protein synthesis [18]. Additionally, 
since the HCMV gene was evolutionarily distant enough from 
HSV-1 genes, it was hypothesized that IRS-1 lacked the 
neurovirulence function of 134.5 and thus could restore late 
viral protein synthesis without restoring neurovirulence. Two 
chimeric HSVs were engineered; C130, a 134.5 HSV 
engineered to express the HCMV TRS1 gene and C134, a 
134.5 HSV engineered to express HCMV IRS1. Results 
indicated that insertion of the HCMV TRS1 or TRS1 gene into 
a 134.5 HSV resulted in a virus with restored late viral protein 
synthesis and improved replication in malignant glioma cells 
both  in vitro and in vivo [19]. This improved replication 
translated to a better anti-tumor response as well, when directly 
compared to tumors treated with parent 134.5 HSV only. 
Importantly, the HSV/HCMV chimeric viruses were also 
demonstrated to be safe following direct intracranial inoculation 
in mice, but with significantly different LD50 values. While the 
LD50  value measured for C134, which expressed IRS1, was 
identical to that of its parent 134.5 HSV, the LD50 value of 
C130, encoding the TRS1 gene, was increased by nearly 100-
fold as compared to C134. Despite the increased virulence of 
C130, both HSV/HCMV chimeric viruses have safety profiles 
similar to oHSV (HSV1716 and G207) that have been 
successfully used in Phase I clinical trials [20, 21]. Due to its 
excellent anti-tumor efficacy and minimal neurotoxicity, C134 
has been advanced for clinical development. An application was 
submitted, and received approval, for production of C134 using 
current Good Manufacturing Practices (cGMP) through the 
National Cancer Institute’s Rapid Access to Intervention 
Development (RAID) Program for the translation of novel 
experimental therapeutics into Phase I trials in patients. 
STANDARD OF CARE THERAPIES IN COMBINATION 
WITH oHSV THERAPY 
  The most recent shift in standard of care treatment 
paradigms for patients with newly diagnosed glioma was 
made following the report that combination of ionizing 
radiation with temozolomide (TMZ) administration resulted 
in significantly improved survival benefit vs treatment with 
either therapy alone [22]. In this study, the median two year 
Table 1.  Past, Present and Pending oHSV Trials in Patients with Malignant Glioma 
 
Virus  Parent Strain  Tumor-Targeting Mutation(s)  Trial Description  Trial Status  References 
Phase 1 dose escalation, safety  closed  [21] 
Phase 1b, single dose, assess 
intratumoral virus replication 
closed [37] 
Phase Ib, safety of resection 
cavity administration 
closed [38] 
HSV1716 17  Both  134.5 gene copies deleted 
Phase III  ongoing  nexxusscotland.com website 
Phase 1 dose escalation, safety  closed  [20] 
Phase Ib, two dose regimen, one 
intratumor, one into resection 
cavity 
closed [17]  G207 F  Both 134.5 gene copies deleted, 
lacZ gene inserted into UL39 gene 
Phase Ib  closed  Markert et al., submitted 
M032 
F/ 
M002 
Both 134.5 gene copies deleted  Phase I, safety and dose 
escalation  pending [15] 
C134 
F/ 
C101 
Both 134.5 gene copies deleted, 
HCMV gene IRS1 introduced 
within UL3/UL4 intergenic region 
Phase I safety and dose 
escalation 
planning 
stages 
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survival of patients treated with the combination therapy was 
over 26% vs 10% two year survival of patients that received 
radiation therapy only. It is not unreasonable to predict that 
combining oncolytic HSV therapies with standard of care 
therapies like ionizing radiation and chemotherapeutic drugs 
would also result in improved survival benefit vs either 
therapy alone. A number of reports support this, and are 
summarized below. 
  134.5HSV and ionizing radiation. In 1998, Advani and 
colleagues demonstrated that administration of high doses of 
ionizing radiation (IR) 24 and 48 hours following direct, 
intratumoral inoculation of R3616, a 1345 HSV, lysed 
glioma tumor explants much more efficiently than treatment 
with either therapy alone [23]. More recently, the underlying 
mechanism mediating enhanced viral replication was linked 
to upregulation of late viral promoters by the host p38 
protein [24]. These results are discussed in more detail 
elsewhere [25]. 
  oHSV therapy in combination with chemotherapeutic 
drugs. Likewise, combination of TMZ treatment with oHSV 
vectors was also shown to improve lysis of tumor cells 
resistant to destruction by either agent alone [26]. Aghi and 
colleagues discovered that the DNA repair mechanisms 
elicited following treatment with TMZ enhance intratumoral 
replication of oHSV and kill tumor cell lines normally 
resistant to either therapy alone. These data support reports 
of combination radiation or chemotherapy with oncolytic 
viral therapy in other malignancies outside the brain [27, 28]. 
TUMOR-SPECIFIC RETARGETING OF oHSV 
  As mentioned earlier, one of the primary limitations of 
the  134.5 HSV platform is their inability to maintain 
efficient replication in CNS tumors. One solution is to 
engineer viruses in which the 134.5 gene is only expressed 
in tumor cells, but not in adjacent normal tissue. Two of the 
strategies developed to enable tumor-specific ICP34.5 
expression are i) to modify virus glycoproteins to enter cells 
via a tumor-specific receptor, while preventing interaction 
with normal cell surface receptors, and ii) to express ICP34.5 
under the control of a tumor-specific promoter. In a series of 
elegant experiments, Zhou and Roizman and colleagues were 
able to re-target a wildtype HSV vector to the IL-13Ralpha2 
receptor, which is expressed on the surface of many 
glioblastoma cell lines, as well as on anaplastic astrocytomas 
[29, 30]. HSV mutant R5111 contains both copies of 34.5 
intact, but the known heparan binding sites on glycoproteinB 
(gB) and gC were mutated. R5111 also contains a chimeric 
gD that was constructed to express IL-13. R5111 was able to 
infect cells following interaction of the chimeric gD/IL13 
with the IL13Ralpha2 on the tumor cell lines tested [31]. 
Mutations were then introduced into R5111 to construct a 
virus (R5141) in which binding to either HveA or nectin-1, 
its native receptor has been completely abolished [32]. 
Current challenges for receptor re-targeted viruses like 
R5141 include development of an appropriate and FDA-
approved cell line for production of highly purified, high 
titer virus stocks for preclinical safety and efficacy testing in 
mice, and for Phase I clinical trials in patients. 
  The second strategy for targeted expression of ICP34.5 
employs the use of tumor-specific promoters driving 
expression of the ICP34.5 protein. One example is the 
promoter for nestin-1, an intermediate filament protein 
shown to be upregulated in a high percentage of human 
glioma cell lines, but not normal human astrocytes. Studies 
by Kambara and colleagues demonstrated that rQNestin34.5, 
an HSV engineered to express ICP34.5 from the nestin-1 
promoter, was able to improve survival of mice bearing 
intracranial tumors as compared to treatment with the parent 
virus (lacking both 134.5 gene copies and containing a 
disrupted UL39 gene) only [33]. In vivo neurotoxicity studies 
showed that rQNestin34.5 was not more neurovirulent than 
its 134.5-deleted parent. 
  Another example of a tumor-specific promoter driving 
ICP34.5 expression is the mutant HSV KeM34.5. KeM34.5 
was derived from G207, but the lacZ gene within the UL39 
gene has been replaced with the Musashi-1 promoter driving 
ICP34.5 expression [34]. Musashi 1 is a neural RNA-binding 
protein whose expression is upregulated in glioma cell lines. 
Treatment of human glioma tumors established intracranially 
in mice resulted in significantly improved survival of tumor 
bearing mice, and this effect was dose-dependent. 
  Thus retargeting of oHSV vectors, either through tumor-
specific receptors allowing specific delivery of wildtype 
virus, or through tumor-specific promoter activity 
controlling ICP34.5, are promising strategies for glioma 
therapy. It remains to be seen whether they will be safe for 
administration in humans. 
CONVECTION-ENHANCED DELIVERY (CED) OF 
oHSV 
  Another obstacle in the treatment of malignant glioma is 
efficient delivery of drugs or therapeutics, including oHSV, 
into the tumor site. The blood brain barrier (BBB) can 
significantly impede delivery of novel therapeutic drugs and 
agents to tumors inaccessible to stereotactic injection of 
oHSV. Even when the tumor mass is accessible, migrating 
tumor cells distal from the primary mass are often left 
untouched, due to inadequate distribution at tumor 
inoculation [35]. One recently described approach to 
improve distribution of oHSV vectors into the tumor mass is 
the use of convection enhanced delivery (CED). In CED, 
multiple catheters are placed stereotactically within the 
tumor mass and surrounding the tumor/resection area. 
Hadjipanayis et al. demonstrated the CED of a replication 
defective HSV vector, d106, significantly improved survival 
of tumor-bearing mice when the therapy was combined with 
IR or TMZ [36]. However there was no significant 
difference in median survival rates of mice treated with d106 
+ CED alone (without IR or TMZ). Nevertheless, CED using 
any of the oHSV vectors described earlier in this review is a 
promising approach to ensure adequate and widespread 
distribution in the tumor. 
ADVANCING ONCOLYTIC HSV VECTORS INTO 
PATIENTS WITH MALIGNANT GLIOMA: STATUS 
OF CLINICAL TRIALS 
  A total of 5 clinical trials in patients utilizing oHSV 
vectors have been published to date [17, 20, 21, 37, 38]. 
These trials were initiated more than a decade ago with the 
first-generation oHSV vectors HSV1716 (United Kingdom) 
and G207 (United States). Both HSV1716 (derived from 
wildtype strain 17) and G207 (derived from wildtype strain HSV Vectors for Brain Tumor Therapy  The Open Virology Journal, 2010, Volume 4    107 
“F”) have one or both of the attenuating mutations (134.5 
deletion and UL39 disruption), respectively, and described 
earlier in this review. The details of these trials have been 
adequately summarized elsewhere [1, 39]. 
  A Phase Ib study has just been completed in which 
ionizing radiation was administered following G207 in a 
group of 9 patients (Markert JM, personal communication) 
and report of the results are pending final analysis. Finally, 
according to their website, [http://www.nexxusscotland.com/ 
life_science/case_studies/organisations/crusade_laboratories], 
Crusade Laboratories in Glasgow, Scotland has initiated a 
Europe-wide Phase III clinical trial using HSV1716. 
  At least two other promising oHSV vectors are close to 
initial Phase I safety studies in patients. cGMP production of 
M032, mentioned earlier, is complete and, pending final 
sterility testing, submission of an IND application to the 
FDA is planned for mid to late 2010. The chimeric 
HSV/HCMV, C134, is also being submitted for cGMP 
production through the NCI BDP. Production date has not 
yet been set, but protocols for growing up high titer virus 
production lots have already been developed and the process 
is anticipated to proceed quickly. Table 1 summarizes the 
past and present oHSV clinical trials in patients, as well as 
second generation viruses poised to enter the clinical trial 
arena in the next 12-18 months. 
CONCLUDING REMARKS 
  The field of oncolytic HSV therapy for treatment of 
malignant glioma continues to evolve with the advent of new 
therapeutics, and discovery of new tumor-specific targets to 
be engineered into oHSV vectors. Examples of novel targets 
include markers of glioma progenitor cells (GPCs), as well 
as tumor-specific delivery and IR-mediated or expression of 
proteins involved in signal transduction pathways. Gene 
expression profile analyses of G207-treated tumor specimens 
from the G207 Phase Ib study [17] should provide new 
insight as to correlates of responders to oHSV therapy vs 
nonresponders. Regardless, inasmuch as the oHSV trials in 
patients to date have overwhelmingly demonstrated safety of 
direct intratumoral inoculation and surrounding adjacent 
tissue, advancement of 2
nd and 3
rd generation viruses into 
Phase I clinical trials, alone and in combination with current 
standard of care therapies, is eagerly anticipated. 
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